TMS uses brief magnetic pulses to influence activity in targeted areas of the brain. The NeuroStar® Advanced Therapy System has specific FDA-cleared psychiatric uses. Its use for memory impairment, mild cognitive impairment, Alzheimer's disease, other dementias, insomnia, or general sleep improvement remains off-label and is still being studied.
NeuroStar has FDA-cleared indications for treating depressive episodes and decreasing associated anxiety symptoms in certain adults with major depressive disorder, as an adjunctive treatment for adults with obsessive-compulsive disorder, and as an adjunctive treatment for major depressive disorder in adolescents ages 15 to 21. For the adult depression indication, the left dorsolateral prefrontal cortex, often shortened to the left DLPFC, is an established target. These clearances apply to the labeled device, indication, protocol, and patient population.
The use of NeuroStar TMS for memory impairment, mild cognitive impairment, Alzheimer's disease, other dementias, insomnia, or general sleep improvement is off-label. These uses are not included in NeuroStar's FDA-cleared labeling, and FDA has not determined through that clearance process that NeuroStar is safe or effective for these conditions.
Off-label does not mean that an application has never been studied. It means the specific use is outside the FDA-cleared labeling, so the quality, relevance, and limitations of the published evidence must be considered carefully.
Gerrish MedEsthetics uses the NeuroStar Advanced Therapy System in Scottsdale and is available to discuss the published research involving TMS, cognition, and sleep. In selected patients, physician-directed off-label use for cognitive or sleep-related concerns may be considered after an individualized medical evaluation.
These uses remain off-label. Published results are mixed, research protocols differ, and no individual benefit can be predicted or guaranteed. Any care provided would be clinical care, not participation in a clinical trial or research study.
TMS is a noninvasive medical technology. A coil placed against the scalp delivers brief magnetic pulses, which create small electrical changes in the targeted outer portion of the brain. TMS does not involve surgery or implanted electrodes.
The result depends not only on the device, but also on where the coil is positioned, how the pulses are delivered, and how often sessions are repeated. This is why findings from one study cannot automatically be applied to every TMS device or protocol.
The brain does not have one universal TMS target. NeuroStar's adult depression protocol commonly targets the left dorsolateral prefrontal cortex, or left DLPFC, a region near the front and side of the brain that participates in several connected networks.
The left DLPFC has also been studied in some cognition trials. Other researchers have targeted both sides of the prefrontal cortex, the precuneus, the medial prefrontal cortex, or several brain regions. Sleep studies have also used different targets and pulse patterns.
For that reason, a result from one TMS study cannot automatically be applied to a different brain target, device, or treatment protocol. A standard left-DLPFC depression protocol should not be assumed to be an established cognition or sleep protocol.
Researchers are asking two related but distinct questions: whether TMS can influence cognitive measures in selected patients, and whether certain stimulation patterns can affect sleep-related brain activity. The evidence is not uniform, which is why each topic has its own review.
Some randomized and sham-controlled studies have reported changes in selected cognitive measures, while other well-designed trials have found little or no advantage over sham treatment. Improvement on a cognitive test is not the same as reversing the underlying disease.
Read the Cognition Evidence ReviewSome trials have reported improvements in subjective sleep scores. Objective findings, protocol consistency, and durability remain less certain, and the protocols studied for sleep are not necessarily the same as the standard left-DLPFC depression protocol.
Read the Sleep Evidence ReviewPublished research does not currently establish that TMS:
The studies below were selected because they help explain both the encouraging findings and the unresolved questions. They should not be read as proof that one device, brain target, or protocol will benefit an individual patient.
Randomized active-versus-sham study with a 2-week intensive phase followed by weekly maintenance through 52 weeks.
48 adults with mild-to-moderate Alzheimer's disease were randomized; 32 completed the study.
Personalized, neuronavigated precuneus rTMS informed by TMS-EEG.
The active group had less worsening than sham on the prespecified CDR-SB outcome and differences on selected cognitive, daily-function, and behavioral measures.
Single-center study with a modest sample, 32 of 48 completing, investigator financial interests disclosed, and a need for independent multicenter replication.
Large multisite, randomized, double-blind, placebo-controlled trial with active-treatment duration groups and longer-term follow-up.
More than 150 participants with mild-to-moderate Alzheimer's disease were enrolled.
Bilateral dorsolateral prefrontal rTMS delivered for 2 or 4 weeks, compared with 4 weeks of sham stimulation.
Active stimulation was not superior to sham on the primary cognitive outcome over the study period.
The neutral result applies most directly to the target and dosing protocol studied and should not automatically be generalized to different network targets or maintenance strategies.
Prospectively registered systematic review and meta-analysis of randomized trials.
19 studies contributed 23 trials involving 1,690 adults with insomnia disorder.
Varied rTMS targets, frequencies, schedules, and comparisons, including real-versus-sham and adjunctive designs.
Pooled subjective sleep measures favored rTMS. Objective pooled data showed a difference in sleep efficiency, but not in total sleep time, sleep onset latency, wake after sleep onset, or REM sleep.
Substantial heterogeneity, varied protocols, relatively few objective sleep studies, and limited follow-up prevented identification of a standardized or durable effect.
Pilot, double-blind, randomized, sham-controlled trial.
62 participants with chronic insomnia were randomized; 41 completed 20 sessions and follow-up.
Active or sham rTMS targeting the medial prefrontal cortex over 4 weeks.
Response and remission rates favored active stimulation at the end of treatment, but the between-group response and remission differences were no longer significant at 4-week follow-up; some symptom measures remained different.
Pilot study with substantial attrition and short follow-up, leaving durability uncertain.
Which brain targets are most relevant for cognition and sleep?
Which pulse patterns and treatment schedules are most appropriate?
Do different stages or causes of cognitive decline respond differently?
Does combining stimulation with cognitive training change the result?
How durable are any observed changes?
Which patients, if any, are most likely to experience a meaningful benefit?
Published TMS research can be difficult to interpret because studies use different devices, brain targets, pulse patterns, treatment schedules, and ways of measuring response.
If you have questions about the research, the NeuroStar system, or whether a physician discussion may be reasonable for you or a family member, you may contact our Scottsdale team. We will explain what the evidence currently suggests, where uncertainty remains, and whether a more formal medical evaluation is appropriate.
Contacting the practice does not mean that TMS will be recommended.
This page summarizes published research and is intended for general education. The use of NeuroStar TMS for memory impairment, mild cognitive impairment, Alzheimer's disease, other dementias, insomnia, or general sleep improvement is off-label and is not included in the FDA-cleared indications discussed above.
Research findings vary by device, brain target, pulse pattern, treatment schedule, patient population, outcome measure, and duration of follow-up. Improvements reported in individual studies do not establish reversal of disease, prevention of progression, or a predictable benefit for any individual.
